Abstract: This invention discloses a new Instant Messaging(IM) routing method and routers, to manage IM servers and provide network addressing, utilizing a management module and a routing module. Among them, the management module is used to maintain the router's own information and the information of IM servers, comprising of: (1) Unique identification Router ID(RID) for every IM router in the entire network, (2) Information of one or multiple servers that every IM router manages, (3) Unique identification Host ID(HID) of every IM server in the entire network, The routing module provides routing method to facilitate the connectivity and communication between the IM servers based on the identification HID and identification RID.

Abstract: The present invention is directed to Compounds of Formula (I) and salts thereof, wherein R1, R2, R3 and R4 are defined above herein. The present invention is also directed to uses of the compounds of Formula (I) to add phosphoramidate groups onto organic alcohols.

Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

Abstract: Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms.

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capab- lities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associate viruses. IN some as- pects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: An optical fiber decoding-based wireless gaming headset includes: an audio digital signal interface (1), a transmitter (2), and a wireless headset body (3). The audio digital signal interface (1) is electrically connected with the transmitter (2). The transmitter (2) is in wireless communication connection with the wireless headset body (3). The audio digital signal interface (1) includes an optical fiber receiving head (11) for receiving a sound optical fiber signal generated by a game console and a USB interface (12). The transmitter (2) includes a photoelectric conversion circuit (21), a USB interface signal receiving circuit (22) and a first wireless transmitting module (23). The wireless headset body (3) includes left and right horns (31), a microphone (32), a second wireless transmitting module (33) and a DA/AD conversion circuit (34).

Abstract: A process for the preparation of N-protected 6-(piperidin-4-ylcarbamoyl)piperidin-3-yl sulfonates of Formula (III): which comprises contacting a lactone of Formula (II): with an azacycloalkylamine of formula (II-Am): followed by contact with a sulfonyl halide of formula (II-Su): R4—SO2W (II-Su) in the presence of tertiary amine base, wherein PG1 and PG2 are amine protective groups; k, p and q are 0, 1, or 2, and W, R2, R3, R4, R5, R6, R7, R8, and R9 are defined herein. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as ?-lactamase inhibitors.

Abstract: Disclosed are capsid-mutated rAAV vectors and methods for their use in gene therapy, and particularly for use in delivering therapeutic transgenes to treat a variety of mammalian diseases and disorders, including dysfunctions and abnormal conditions of the human eye. VP3 capsid proteins comprising a modification of one or more of the surface-exposed tyrosine residues are disclosed, and in particular, VP3 capsid protein comprising tyrosine-to-phenylalanine mutations at positions corresponding to Y444F, Y500F, and Y730F of the wild-type AAV2 sequence. Also provided are rAAV virions and viral particles that comprise such a mutated AAV capsid protein and a nucleic acid molecule that expresses one or more selected therapeutic or reporter transgenes in one or more mammalian cells of interest. Advantageously, the capsid-mutated rAAV vectors and virions disclosed herein afford improved transduction efficiency in a variety of cells, tissues and organs of interest, when compared to their unmodified (i.e.

Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.

Abstract: The disclosure provides an arrangement structure suitable for an inverted pulverized coal boiler with ultra-high steam temperature steam parameters, including a hearth, wherein the hearth is communicated with a middle uplink flue, and the top of the middle uplink flue is communicated with that of a tail downlink flue. In the structure, the hearth is connected with the middle uplink flue by a hearth outlet horizontal flue at the bottom, so that the high-temperature gas is drained to a low elevation and then flows upwards through the middle uplink flue; a final heating surface may be arranged at the low position of the hearth outlet horizontal flue and the middle uplink flue so as to reduce the length of the high-temperature steam pipeline between the final heating surface and the steam turbine, lower the manufacturing cost of the boiler as well as the frication and radiation loss of the pipe.

Abstract: An optical fiber decoding-based wireless gaming headset includes: an audio digital signal interface (1), a transmitter (2), and a wireless headset body (3). The audio digital signal interface (1) is electrically connected with the transmitter (2). The transmitter (2) is in wireless communication connection with the wireless headset body (3). The audio digital signal interface (1) includes an optical fiber receiving head (11) for receiving a sound optical fiber signal generated by a game console and a USB interface (12). The transmitter (2) includes a photoelectric conversion circuit (21), a USB interface signal receiving circuit (22) and a first wireless transmitting module (23). The wireless headset body (3) includes left and right horns (31), a microphone (32), a second wireless transmitting module (33) and a DA/AD conversion circuit (34).

Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.

Abstract: Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms.

Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.

Abstract: A process for the preparation of N-protected 6-(piperidin-4-ylcarbamoyl)piperidin-3-yl sulfonates of Formula (III): which comprises contacting a lactone of Formula (II): with an azacycloalkylamine of formula (II-Am): followed by contact with a sulfonyl halide of formula (II-Su): R4—SO2W (II-Su) in the presence of tertiary amine base, wherein PG1 and PG2 are amine protective groups; k, p and q are 0, 1, or 2, and W, R2, R3, R4, R5, R6, R7, R8, and R9 are defined herein. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as ?-lactamase inhibitors.

Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.

Abstract: The disclosure encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, having less steps and improved yields as compared to previous synthetic methods for making these compounds, which are CGRP receptor antagonists, useful for the treatment of migraine. Conditions for an amide bond formation between an acid and amine include for example reacting the compounds of Formulae B (after salt break) and C with an amide coupling reagent and optionally an additive and an acid and/or a base in a non-reactive solvent.

Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.

Abstract: A first aspect of the present invention describes a compound selected from group consisting of: wherein R is either H, C(O)RA, or C(O)NHCH(X)COOH; provided that X is a C2-C6 alkyl, or a C3-C8 cycloalkyl and RA is a C1-6 alkyl or aryl; These compounds are used to make Compound A